Trial: A Phase III Study of Dato-DXd With or W…

Trial Details

Sponsor: AstraZeneca (industry)

Phase: 3

Start date: Nov. 23, 2023

Planned enrollment: 625

Trial ID: NCT06103864

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Datopotamab deruxtecan (Dato-DXd, DS-1062)

Overview

Datopotamab deruxtecan (Dato‑DXd; DS‑1062; US brand name Datroway) is a TROP2‑directed antibody–drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca. In the United States, it is FDA‑approved for: - Unresectable or metastatic HR‑positive/HER2‑negative breast cancer after prior endocrine therapy and chemotherapy (January 17, 2025). (fda.gov) - Locally advanced or metastatic EGFR‑mutated NSCLC after prior EGFR‑directed therapy and platinum chemotherapy (accelerated approval, June 23, 2025). (fda.gov)

Large phase 3 trials have reported improved progression‑free survival vs chemotherapy in HR+/HER2− breast cancer (TROPION‑Breast01) and in previously treated NSCLC overall (TROPION‑Lung01), with the clearest benefit in nonsquamous NSCLC; overall survival in Lung01 did not reach statistical significance in the all‑comers population. (ascopubs.org)

Mechanism of action

Dato‑DXd is a humanized anti‑TROP2 IgG1 linked via a cleavable tetrapeptide linker to a membrane‑permeable topoisomerase I inhibitor payload (DXd); the average drug–antibody ratio is ~4. Upon TROP2 binding and internalization, lysosomal cleavage releases DXd, causing DNA damage and apoptosis. Preclinical studies also show “bystander” killing of adjacent low‑TROP2 tumor cells. (pubmed.ncbi.nlm.nih.gov)

Dosing used in pivotal trials and in US labeling is 6 mg/kg IV every 3 weeks (capped at 540 mg for ≥90 kg). (pubmed.ncbi.nlm.nih.gov)

Efficacy

Breast cancer (HR+/HER2−, previously treated) - TROPION‑Breast01 (phase 3, n≈732): Dato‑DXd significantly improved PFS vs investigator’s‑choice single‑agent chemotherapy (BICR HR 0.63; 95% CI 0.52–0.76; median 6.9 vs 4.9 months). Confirmed ORR 36.4% vs 22.9%. OS was immature at the primary analysis (HR 0.84; 95% CI 0.62–1.14). These data supported the US approval. (ascopubs.org)

NSCLC (previously treated, all histologies) - TROPION‑Lung01 (phase 3, n=604): PFS benefit vs docetaxel (median 4.4 vs 3.7 months; HR 0.75; P=0.004); OS not statistically significant in the overall population (median 12.9 vs 11.8 months; HR 0.94; P=0.53). Benefit was most pronounced in nonsquamous NSCLC. (pubmed.ncbi.nlm.nih.gov)

NSCLC (nonsquamous subgroup from Lung01; descriptive) - Nonsquamous subgroup showed higher activity: ORR 31.2% vs 12.8% with docetaxel; median PFS 5.5 vs 3.6 months; OS 14.6 vs 12.3 months (HR 0.84). OS did not meet significance in the overall study. (iaslc.org)

EGFR‑mutated NSCLC (post‑EGFR TKI and platinum) - Pooled analysis (TROPION‑Lung05 phase 2 + Lung01 subset; n≈117): confirmed ORR 42.7% (95% CI 33.6–52.2), median DOR 7.0 months, median PFS 5.8 months, median OS 15.6 months. These data supported the US accelerated approval. (daiichisankyo.us)

Early‑phase breast cancer cohorts - TROPION‑PanTumor01 (phase 1): in heavily pretreated HR+/HER2− and TNBC cohorts, BICR ORR 26.8% and 31.8%, with median PFS 8.3 and 4.4 months, respectively. (ascopubs.org)

Safety

Class‑consistent risks include stomatitis/oral mucositis, nausea, ocular events, alopecia, and interstitial lung disease (ILD)/pneumonitis.

Breast (TROPION‑Breast01): grade ≥3 treatment‑related AEs were lower with Dato‑DXd vs chemo (20.8% vs 44.7%). Additional safety analyses reported stomatitis/oral mucositis in 56%, ocular events in 40%, and adjudicated drug‑related ILD in 3% (mostly low grade). (ascopubs.org)
NSCLC (TROPION‑Lung01): stomatitis ~47% and nausea ~34% with Dato‑DXd; grade ≥3 TRAEs 26% vs 42% with docetaxel; pneumonitis/ILD ~4%. No late safety signals with extended follow‑up. (ascopost.com)
Stomatitis management and incidence across trials are detailed in a peer‑reviewed review and show mostly grade 1–2 events with early onset; implementation of prophylaxis/management guidelines reduced frequency and severity. (academic.oup.com)
Pooled ILD analysis across breast and lung trials reported adjudicated drug‑related ILD in ~5% (mostly grade 1–2), with rare grade ≥3 events; careful monitoring is recommended. US labeling includes boxed/serious warnings for ILD/pneumonitis, ocular adverse reactions, and stomatitis. (ovid.com)

HealthScout AI Analysis

Goal: To determine whether datopotamab deruxtecan (Dato-DXd) plus durvalumab improves progression-free survival versus investigator’s choice chemotherapy plus pembrolizumab in PD-L1–positive locally recurrent inoperable or metastatic triple-negative breast cancer, and to assess overall survival, antitumor activity, safety, and impact on quality of life. The study also explores the contribution of Dato-DXd monotherapy.

Patients: Adults with histologically or cytologically confirmed locally recurrent inoperable or metastatic triple-negative breast cancer, PD-L1 positive by 22C3 CPS ≥10, no prior systemic therapy for advanced disease, ECOG 0–1, measurable disease by RECIST 1.1, and adequate organ function. Prior (neo)adjuvant therapy allowed if recurrence occurred ≥6 months after completion. Stable, treated, asymptomatic brain metastases may be eligible. Key exclusions include uncontrolled comorbidities, significant cardiac disease, active ILD/pneumonitis or history requiring steroids, uncontrolled infections including active HBV/HCV or poorly controlled HIV, clinically significant corneal disease, active autoimmune disease, and prior TROP2-directed or topoisomerase I–containing ADCs.

Design: International, multicenter, open-label, randomized Phase III, three-arm trial with approximately 625 participants. Randomization is stratified by geography, disease-free interval (de novo vs 6–12 months vs >12 months), and prior PD-1/PD-L1 therapy in early-stage TNBC. The primary comparison is Dato-DXd + durvalumab versus chemotherapy + pembrolizumab, with Dato-DXd monotherapy as an additional experimental arm.

Treatments: Arm 1: Dato-DXd plus durvalumab. Arm 2: Investigator’s choice chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin) plus pembrolizumab, a PD-1 inhibitor standard in PD-L1–positive metastatic TNBC. Arm 3: Dato-DXd monotherapy. Dato-DXd is an investigational TROP2-directed antibody-drug conjugate composed of a humanized anti-TROP2 IgG1 linked via a cleavable tetrapeptide to a membrane-permeable topoisomerase I inhibitor payload (DXd). After binding TROP2 and internalization, DXd is released to induce DNA damage; bystander killing can occur due to payload permeability. In prior Phase III studies, Dato-DXd improved PFS versus docetaxel in previously treated metastatic NSCLC and achieved PFS benefit in HR+/HER2− breast cancer, with a manageable safety profile; ILD/pneumonitis remains an adverse event of special interest.

Outcomes: Primary: Progression-free survival by BICR per RECIST 1.1. Key secondary endpoints include overall survival, objective response rate, duration of response, investigator-assessed PFS, 24-week clinical benefit rate, patient-reported outcomes (time to deterioration in breast/arm symptoms, pain, physical function, and global health status/quality of life), time to first and second subsequent therapy, PFS2, pharmacokinetics and immunogenicity of Dato-DXd with durvalumab, and safety/tolerability (adverse events).

Burden on patient: Moderate. Requirements include central confirmation of PD-L1 positivity and provision of a recent FFPE tumor sample, with potential need for a new biopsy if metastatic tissue is unavailable. Imaging for RECIST assessments will occur at regular intervals typical of Phase III metastatic studies. Patients on Dato-DXd±durvalumab will have infusion visits and additional safety monitoring for stomatitis, ocular symptoms, and pulmonary events; targeted assessments for ILD/pneumonitis may include baseline and symptom-triggered imaging and pulmonology evaluation. The trial includes PRO questionnaires and, for combination therapy, pharmacokinetic and immunogenicity blood draws over multiple cycles, adding visit time. Comparator arm involves standard chemo-immunotherapy infusions and routine laboratory and toxicity monitoring. Travel and visit frequency are in line with standard first-line metastatic TNBC trials, but added PK/ADA sampling and vigilant ILD monitoring increase procedural intensity compared with routine care.

Last updated: Oct 2025

Eligibility

Show Criteria

Key Inclusion Criteria

* Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.

* ECOG PS 0 or 1.

* Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. If no such sample is available, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start).

* PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.

* No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.

- Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.

* Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).

* Measurable disease as per RECIST 1.1.

* Adequate bone marrow reserve and organ function.

* Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception.

Key Exclusion Criteria

* As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.

* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before Cycle 1 Day 1 and of low potential risk for recurrence.

* Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.

- Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.

* Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.

* Active or uncontrolled hepatitis B or C virus infection.

* Known HIV infection that is not well controlled.

* Uncontrolled or significant cardiac disease.

* History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.

* Severe pulmonary function compromise.

* Clinically significant corneal disease.

* Active or prior documented autoimmune or inflammatory disorders.

* Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.

* Any concurrent anti-cancer treatment.

* Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.

* Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.

Sites (308)

Sort by distance to:

Research Site

Buenos Aires, C1125ABD, Argentina

No email / No phone

Status: Recruiting

Research Site

San Nicolás de los Arroyos, B2900, Argentina

No email / No phone

Status: Recruiting

Research Site

Rosario, 2000, Argentina

No email / No phone

Status: Recruiting

Research Site

Ciudad de Buenos Aires, C1015ABO, Argentina

No email / No phone

Status: Recruiting

Research Site

CABA, 1425, Argentina

No email / No phone

Status: Recruiting

Research Site

CABA, 1414, Argentina

No email / No phone

Status: Recruiting

Research Site

Heidelberg, 3084, Australia

No email / No phone

Status: Recruiting

Research Site

Darlinghurst, 2010, Australia

No email / No phone

Status: Recruiting

Research Site

Camperdown, 2050, Australia

No email / No phone

Status: Recruiting

Research Site

Waratah, 2298, Australia

No email / No phone

Status: Recruiting

Research Site

Nedlands, 6009, Australia

No email / No phone

Status: Recruiting

Research Site

Melbourne, 3000, Australia

No email / No phone

Status: Recruiting

Research Site

Recife, 52010-075, Brazil

No email / No phone

Status: Recruiting

Research Site

Porto Alegre, 90035-003, Brazil

No email / No phone

Status: Recruiting

Research Site

Itajaí, 88301-220, Brazil

No email / No phone

Status: Recruiting

Research Site

Goiânia, 74000-000, Brazil

No email / No phone

Status: Recruiting

Research Site

Florianópolis, 88034-000, Brazil

No email / No phone

Status: Recruiting

Research Site

Curitiba, 80730-150, Brazil

No email / No phone

Status: Recruiting

Research Site

Barretos, 14784-400, Brazil

No email / No phone

Status: Recruiting

Research Site

Teresina, 64049-200, Brazil

No email / No phone

Status: Recruiting

Research Site

São Paulo, 01317-001, Brazil

No email / No phone

Status: Recruiting

Research Site

São Paulo, 01246-000, Brazil

No email / No phone

Status: Recruiting

Research Site

Toronto, Ontario, M5G 2M9, Canada

No email / No phone

Status: Recruiting

Research Site

Hamilton, Ontario, L8V 5C2, Canada

No email / No phone

Status: Recruiting

Research Site

Barrie, Ontario, L4M 6M2, Canada

No email / No phone

Status: Recruiting

Research Site

Québec, Quebec, G1S 4L8, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H4A 3J1, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H2X 0A9, Canada

No email / No phone

Status: Recruiting

Research Site

Greenfield Park, Quebec, J4V 2H1, Canada

No email / No phone

Status: Recruiting

Research Site

Saskatoon, Saskatchewan, S7N 4H4, Canada

No email / No phone

Status: Recruiting

Research Site

Regina, Saskatchewan, S4T 7T1, Canada

No email / No phone

Status: Recruiting

Research Site

Nanning, 530021, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450052, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450008, China

No email / No phone

Status: Recruiting

Research Site

Xuzhou, 221009, China

No email / No phone

Status: Recruiting

Research Site

Xintai, 54031, China

No email / No phone

Status: Recruiting

Research Site

Xiamen, 361003, China

No email / No phone

Status: Recruiting

Research Site

Xi'an, 710061, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430079, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430022, China

No email / No phone

Status: Recruiting

Research Site

Wenzhou, 325000, China

No email / No phone

Status: Recruiting

Research Site

Tianjin, 300000, China

No email / No phone

Status: Recruiting

Research Site

Shenyang, 110004, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200080, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200025, China

No email / No phone

Status: Recruiting

Research Site

Shandong, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510060, China

No email / No phone

Status: Recruiting

Research Site

Nanjing, 210009, China

No email / No phone

Status: Recruiting

Research Site

Nanjing, 2100008, China

No email / No phone

Status: Recruiting

Research Site

Nanchang, 330009, China

No email / No phone

Status: Recruiting

Research Site

Jinan, 250021, China

No email / No phone

Status: Recruiting

Research Site

Hefei, 230031, China

No email / No phone

Status: Recruiting

Research Site

Harbin, 150081, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310022, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310016, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510700, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510120, China

No email / No phone

Status: Recruiting

Research Site

Beijing, 100044, China

No email / No phone

Status: Recruiting

Research Site

Beijing, 100142, China

No email / No phone

Status: Recruiting

Research Site

Bengbu, 233004, China

No email / No phone

Status: Recruiting

Research Site

Changchun, 130021, China

No email / No phone

Status: Recruiting

Research Site

Changsha, 410008, China

No email / No phone

Status: Recruiting

Research Site

Changsha, 410013, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610000, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610041, China

No email / No phone

Status: Recruiting

Research Site

Fuzhou, 350014, China

No email / No phone

Status: Recruiting

Research Site

Lille, 59000, France

No email / No phone

Status: Recruiting

Research Site

Paris, 75020, France

No email / No phone

Status: Recruiting

Research Site

Saint-Herblain, 44805, France

No email / No phone

Status: Recruiting

Research Site

Villejuif, 94800, France

No email / No phone

Status: Recruiting

Research Site

Vandœuvre-lès-Nancy, 54511, France

No email / No phone

Status: Recruiting

Research Site

Toulouse, 31059, France

No email / No phone

Status: Recruiting

Research Site

Montpellier, 34298, France

No email / No phone

Status: Recruiting

Research Site

Lyon, 69373, France

No email / No phone

Status: Recruiting

Research Site

Mohali, 160055, India

No email / No phone

Status: Recruiting

Research Site

Mysuru, 570017, India

No email / No phone

Status: Recruiting

Research Site

Nagpur, 440001, India

No email / No phone

Status: Recruiting

Research Site

Nashik, 422009, India

No email / No phone

Status: Recruiting

Research Site

New Delhi, 110075, India

No email / No phone

Status: Recruiting

Research Site

New Delhi, 11029, India

No email / No phone

Status: Recruiting

Research Site

Puducherry, 605006, India

No email / No phone

Status: Recruiting

Research Site

Surat, 395002, India

No email / No phone

Status: Recruiting

Research Site

Thiruvananthapuram, 695011, India

No email / No phone

Status: Recruiting

Research Site

Vadodara, 391760, India

No email / No phone

Status: Recruiting

Research Site

Chennai, 600031, India

No email / No phone

Status: Recruiting

Research Site

Marg Jaipur, 302004, India

No email / No phone

Status: Recruiting

Research Site

Milan, 20141, Italy

No email / No phone

Status: Recruiting

Research Site

Empoli, 50053, Italy

No email / No phone

Status: Recruiting

Research Site

Milan, 20132, Italy

No email / No phone

Status: Recruiting

Research Site

Napoli, 80131, Italy

No email / No phone

Status: Recruiting

Research Site

Padua, 35128, Italy

No email / No phone

Status: Recruiting

Research Site

Reggio Emilia, 42123, Italy

No email / No phone

Status: Recruiting

Research Site

Roma, 00168, Italy

No email / No phone

Status: Recruiting

Research Site

Rozzano, 20089, Italy

No email / No phone

Status: Recruiting

Research Site

Kashiwa, 277-8577, Japan

No email / No phone

Status: Recruiting

Research Site

Kamogawa-shi, 296-8602, Japan

No email / No phone

Status: Recruiting

Research Site

Isehara-shi, 259-1193, Japan

No email / No phone

Status: Recruiting

Research Site

Hiroshima, 734-8551, Japan

No email / No phone

Status: Recruiting

Research Site

Kurume-shi, 830-0011, Japan

No email / No phone

Status: Recruiting

Research Site

Hiroshima, 730-8518, Japan

No email / No phone

Status: Recruiting

Research Site

Hidaka-shi, 350-1298, Japan

No email / No phone

Status: Recruiting

Research Site

Yokohama, 241-8515, Japan

No email / No phone

Status: Recruiting

Research Site

Sendai, 980-8574, Japan

No email / No phone

Status: Recruiting

Research Site

Shinagawa-ku, 142-8666, Japan

No email / No phone

Status: Recruiting

Research Site

Sapporo, 003-0804, Japan

No email / No phone

Status: Recruiting

Research Site

Shinjuku-ku, 160-0023, Japan

No email / No phone

Status: Recruiting

Research Site

Shinjuku-ku, 162-8655, Japan

No email / No phone

Status: Recruiting

Research Site

Tsu, 514-8507, Japan

No email / No phone

Status: Recruiting

Research Site

Tsukuba, 305-8577, Japan

No email / No phone

Status: Recruiting

Research Site

Ota-shi, 373-8550, Japan

No email / No phone

Status: Recruiting

Research Site

Osakasayama-shi, 589-8511, Japan

No email / No phone

Status: Recruiting

Research Site

Osaka, 541-8567, Japan

No email / No phone

Status: Recruiting

Research Site

Okayama, 700-8558, Japan

No email / No phone

Status: Recruiting

Research Site

Nishinomiya-shi, 663-8501, Japan

No email / No phone

Status: Recruiting

Research Site

Niigata, 951-8566, Japan

No email / No phone

Status: Recruiting

Research Site

Nagoya, 467-8602, Japan

No email / No phone

Status: Recruiting

Research Site

Nagoya, 466-8560, Japan

No email / No phone

Status: Recruiting

Research Site

Matsuyama, 791-0280, Japan

No email / No phone

Status: Recruiting

Research Site

Gifu, 501-1194, Japan

No email / No phone

Status: Recruiting

Research Site

Fukushima, 960-1295, Japan

No email / No phone

Status: Recruiting

Research Site

Fukuoka, 811-1395, Japan

No email / No phone

Status: Recruiting

Research Site

Chūōku, 104-0045, Japan

No email / No phone

Status: Recruiting

Research Site

Chiba, 260-8717, Japan

No email / No phone

Status: Recruiting

Research Site

Bunkyō City, 113-8677, Japan

No email / No phone

Status: Recruiting

Research Site

Bunkyō City, 113-8431, Japan

No email / No phone

Status: Recruiting

Research Site

Akashi-shi, 673-8558, Japan

No email / No phone

Status: Recruiting

Research Site

Kumamoto, 860-8556, Japan

No email / No phone

Status: Recruiting

Research Site

Kōtoku, 135-8550, Japan

No email / No phone

Status: Recruiting

Research Site

Kitaadachi-gun, 362-0806, Japan

No email / No phone

Status: Recruiting

Research Site

Mexico City, 0 3100, Mexico

No email / No phone

Status: Recruiting

Research Site

México, 04700, Mexico

No email / No phone

Status: Recruiting

Research Site

México, 6760, Mexico

No email / No phone

Status: Recruiting

Research Site

Cebu City, 6000, Philippines

No email / No phone

Status: Recruiting

Research Site

City of Muntinlupa, 1780, Philippines

No email / No phone

Status: Recruiting

Research Site

Manila, 1000, Philippines

No email / No phone

Status: Recruiting

Research Site

Quezon City, 1112, Philippines

No email / No phone

Status: Recruiting

Research Site

San Juan City, 1502, Philippines

No email / No phone

Status: Recruiting

Research Site

Bacolod, 6100, Philippines

No email / No phone

Status: Recruiting

Research Site

Singapore, 169610, Singapore

No email / No phone

Status: Recruiting

Research Site

Pretoria, 0081, South Africa

No email / No phone

Status: Recruiting

Research Site

Cape Town, 7570, South Africa

No email / No phone

Status: Recruiting

Research Site

Johannesburg, 2013, South Africa

No email / No phone

Status: Recruiting

Research Site

Johannesburg, 2193, South Africa

No email / No phone

Status: Recruiting

Research Site

Johannesburg, 2196, South Africa

No email / No phone

Status: Recruiting

Research Site

Paarl, 7646, South Africa

No email / No phone

Status: Recruiting

Research Site

Seoul, 06591, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 06351, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 06273, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 05505, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03722, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03080, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 02841, South Korea

No email / No phone

Status: Recruiting

Research Site

Seongnam-si, 13620, South Korea

No email / No phone

Status: Recruiting

Research Site

Goyang-si, 10408, South Korea

No email / No phone

Status: Recruiting

Research Site

Daegu, 41404, South Korea

No email / No phone

Status: Recruiting

Research Site

Santander, 39008, Spain

No email / No phone

Status: Recruiting

Research Site

Barcelona, 8035, Spain

No email / No phone

Status: Recruiting

Research Site

Granada, 18016, Spain

No email / No phone

Status: Recruiting

Research Site

Hospitalet deLlobregat, 08907, Spain

No email / No phone

Status: Recruiting

Research Site

Madrid, 28007, Spain

No email / No phone

Status: Recruiting

Research Site

Pamplona, 31008, Spain

No email / No phone

Status: Recruiting

Research Site

Hsinchu, 300, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taoyuan District, 333, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 11259, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 10449, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 100, Taiwan

No email / No phone

Status: Recruiting

Research Site

Tainan City, 704, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taichung, 40447, Taiwan

No email / No phone

Status: Recruiting

Research Site

Kaohsiung City, 80756, Taiwan

No email / No phone

Status: Recruiting

Research Site

Bangkok, 10400, Thailand

No email / No phone

Status: Recruiting

Research Site

Bangkok, 10330, Thailand

No email / No phone

Status: Recruiting

Research Site

Bangkok, 10210, Thailand

No email / No phone

Status: Recruiting

Research Site

Songkhla, 90110, Thailand

No email / No phone

Status: Recruiting

Research Site

Khon Kaen, 40002, Thailand

No email / No phone

Status: Recruiting

Research Site

Dusit, 10300, Thailand

No email / No phone

Status: Recruiting

Research Site

Chiang Mai, 50200, Thailand

No email / No phone

Status: Recruiting

Research Site

Ankara, 6200, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Ankara, 06520, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Samsun, 55200, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Küçükçekmece, 34295, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Besevler Ankara, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Liverpool, L7 8YA, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Chelsea, SW3 6JJ, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Cardiff, CF14 2TL, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Taunton, TA1 5DA, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Sutton, SM2 5PT, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Oxford, OX3 7LE, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, EC1A 7BE, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Leicester, Le5 4PW, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Daphne, Alabama, 36526, United States

No email / No phone

Status: Recruiting

Research Site

Springdale, Arkansas, 72762, United States

No email / No phone

Status: Recruiting

Research Site

Sacramento, California, 95817, United States

No email / No phone

Status: Recruiting

Research Site

Glendale, California, 91204, United States

No email / No phone

Status: Recruiting

Research Site

Aurora, Colorado, 80012, United States

No email / No phone

Status: Recruiting

Research Site

New Haven, Connecticut, 06510, United States

No email / No phone

Status: Recruiting

Research Site

Plantation, Florida, 33324, United States

No email / No phone

Status: Recruiting

Research Site

Miami, Florida, 33176, United States

No email / No phone

Status: Recruiting

Research Site

Jacksonville, Florida, 32256, United States

No email / No phone

Status: Recruiting

Research Site

Chicago, Illinois, 60637, United States

No email / No phone

Status: Recruiting

Research Site

Des Moines, Iowa, 50309, United States

No email / No phone

Status: Recruiting

Research Site

Baton Rouge, Louisiana, 70809, United States

No email / No phone

Status: Recruiting

Research Site

Columbia, Maryland, 21044, United States

No email / No phone

Status: Recruiting

Research Site

Detroit, Michigan, 48201, United States

No email / No phone

Status: Recruiting

Research Site

Saint Paul, Minnesota, 55109, United States

No email / No phone

Status: Recruiting

Research Site

St Louis, Missouri, 63129, United States

No email / No phone

Status: Recruiting

Research Site

Albuquerque, New Mexico, 87109, United States

No email / No phone

Status: Recruiting

Research Site

New York, New York, 10065, United States

No email / No phone

Status: Recruiting

Research Site

Stony Brook, New York, 11794-7263, United States

No email / No phone

Status: Recruiting

Research Site

Cincinnati, Ohio, 45219, United States

No email / No phone

Status: Recruiting

Research Site

Cincinnati, Ohio, 45245, United States

No email / No phone

Status: Recruiting

Research Site

Cleveland, Ohio, 44195, United States

No email / No phone

Status: Recruiting

Research Site

Providence, Rhode Island, 02903, United States

No email / No phone

Status: Recruiting

Research Site

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Recruiting

Research Site

Chattanooga, Tennessee, 37404, United States

No email / No phone

Status: Recruiting

Research Site

El Paso, Texas, 79902, United States

No email / No phone

Status: Recruiting

Research Site

Sugar Land, Texas, 77479, United States

No email / No phone

Status: Recruiting

Research Site

Dallas, Texas, 75246, United States

No email / No phone

Status: Recruiting

Research Site

Fairfax, Virginia, 22031, United States

No email / No phone

Status: Recruiting

Research Site

Midlothian, Virginia, 23114, United States

No email / No phone

Status: Recruiting

Research Site

Norfolk, Virginia, 23502, United States

No email / No phone

Status: Recruiting

Research Site

Roanoke, Virginia, 24014, United States

No email / No phone

Status: Recruiting

Research Site

Charlottesville, Virginia, 22903, United States

No email / No phone

Status: Recruiting

Research Site

Tacoma, Washington, 98405, United States

No email / No phone

Status: Recruiting

Research Site

Hồ Chí Minh, 700000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Ho Chi Minh City, 700000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Hanoi, 100000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Vinh, 460000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Zhanjiang, 524003, China

No email / No phone

Status: Not yet recruiting

Research Site

Anyang, 455000, China

No email / No phone

Status: Not yet recruiting

Research Site

Hong Kong, HKG, Hong Kong

No email / No phone

Status: Not yet recruiting

Research Site

Hong Kong, 999077, Hong Kong

No email / No phone

Status: Not yet recruiting

Research Site

Shatin, 00000, Hong Kong

No email / No phone

Status: Not yet recruiting

Research Site

Hong Kong, Hong Kong

No email / No phone

Status: Not yet recruiting

Research Site

Jaipur, 302004, India

No email / No phone

Status: Not yet recruiting

Research Site

Bergamo, 24127, Italy

No email / No phone

Status: Not yet recruiting

Research Site

CD Mexico, 04980, Mexico

No email / No phone

Status: Not yet recruiting

Research Site

Guadalajara, 44638, Mexico

No email / No phone

Status: Not yet recruiting

Research Site

Tuxtla Gutiérrez, 29090, Mexico

No email / No phone

Status: Not yet recruiting

Research Site

Gdansk, 80-952, Poland

No email / No phone

Status: Not yet recruiting

Research Site

Warsaw, 02-781, Poland

No email / No phone

Status: Not yet recruiting

Research Site

Lodz, 90-302, Poland

No email / No phone

Status: Not yet recruiting

Research Site

Singapore, 308433, Singapore

No email / No phone

Status: Not yet recruiting

Research Site

Singapore, 217562, Singapore

No email / No phone

Status: Not yet recruiting

Research Site

Việt Trì, 35000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Da Nang, 550000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Huế, 530000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Busan, 49241, South Korea

No email / No phone

Status: Completed

Research Site

CABA, C1425, Argentina

No email / No phone

Status: Withdrawn

Research Site

Chongqing, 400030, China

No email / No phone

Status: Withdrawn

Research Site

Georgsmarienhütte, 49124, Germany

No email / No phone

Status: Withdrawn

Research Site

Hamburg, 20357, Germany

No email / No phone

Status: Withdrawn

Research Site

Hanover, 30625, Germany

No email / No phone

Status: Withdrawn

Research Site

Heidelberg, 69120, Germany

No email / No phone

Status: Withdrawn

Research Site

Heilbronn, 74078, Germany

No email / No phone

Status: Withdrawn

Research Site

Leipzig, 04103, Germany

No email / No phone

Status: Withdrawn

Research Site

Düsseldorf, 40479, Germany

No email / No phone

Status: Withdrawn

Research Site

Essen, 45136, Germany

No email / No phone

Status: Withdrawn

Research Site

Visakhapatnam, 530053, India

No email / No phone

Status: Withdrawn

Research Site

Calicut, 673601, India

No email / No phone

Status: Withdrawn

Research Site

Kochi, 682027, India

No email / No phone

Status: Withdrawn

Research Site

Kolkata, 700160, India

No email / No phone

Status: Withdrawn

Research Site

Modena, 41124, Italy

No email / No phone

Status: Withdrawn

Research Site

Guadalajara, 44670, Mexico

No email / No phone

Status: Withdrawn

Research Site

Przemyśl, 37-700, Poland

No email / No phone

Status: Withdrawn

Research Site

Bialystok, 15-027, Poland

No email / No phone

Status: Withdrawn

Research Site

Bydgoszcz, 85-796, Poland

No email / No phone

Status: Withdrawn

Research Site

Gdynia, 81-519, Poland

No email / No phone

Status: Withdrawn

Research Site

Konin, 62-500, Poland

No email / No phone

Status: Withdrawn

Research Site

Krakow, 31-115, Poland

No email / No phone

Status: Withdrawn

Research Site

Legnica, 59-220, Poland

No email / No phone

Status: Withdrawn

Research Site

Wroclaw, 53-413, Poland

No email / No phone

Status: Withdrawn

Research Site

Lublin, 20-090, Poland

No email / No phone

Status: Withdrawn

Research Site

Singapore, 119228, Singapore

No email / No phone

Status: Withdrawn

Research Site

Barcelona, 08028, Spain

No email / No phone

Status: Withdrawn

Research Site

Madrid, 28034, Spain

No email / No phone

Status: Withdrawn

Research Site

Izmir, 35575, Turkey (Türkiye)

No email / No phone

Status: Withdrawn

Research Site

London, SW17 0QT, United Kingdom

No email / No phone

Status: Withdrawn

Research Site

Santa Rosa, California, 95403, United States

No email / No phone

Status: Withdrawn

Research Site

Duarte, California, 91010, United States

No email / No phone

Status: Withdrawn

Research Site

Palm Bay, Florida, 32909, United States

No email / No phone

Status: Withdrawn

Research Site

Honolulu, Hawaii, 96819, United States

No email / No phone

Status: Withdrawn

Research Site

Naperville, Illinois, 60540, United States

No email / No phone

Status: Withdrawn

Research Site

Elmhurst, Illinois, 60126, United States

No email / No phone

Status: Withdrawn

Research Site

Decatur, Illinois, 62526, United States

No email / No phone

Status: Withdrawn

Research Site

New Albany, Indiana, 47150, United States

No email / No phone

Status: Withdrawn

Research Site

Lexington, Kentucky, 40503, United States

No email / No phone

Status: Withdrawn

Research Site

Louisville, Kentucky, 40202, United States

No email / No phone

Status: Withdrawn

Research Site

Louisville, Kentucky, 40207, United States

No email / No phone

Status: Withdrawn

Research Site

Baton Rouge, Louisiana, 70808, United States

No email / No phone

Status: Withdrawn

Research Site

Baltimore, Maryland, 21215, United States

No email / No phone

Status: Withdrawn

Research Site

Worcester, Massachusetts, 01655, United States

No email / No phone

Status: Withdrawn

Research Site

Boston, Massachusetts, 02111, United States

No email / No phone

Status: Withdrawn

Research Site

Grand Rapids, Michigan, 49503, United States

No email / No phone

Status: Withdrawn

Research Site

Hattiesburg, Mississippi, 39401, United States

No email / No phone

Status: Withdrawn

Research Site

Albany, New York, 12206, United States

No email / No phone

Status: Withdrawn

Research Site

York, Pennsylvania, 17403, United States

No email / No phone

Status: Withdrawn

Research Site

McKinney, Texas, 75071, United States

No email / No phone

Status: Withdrawn

Research Site

Flower Mound, Texas, 75028, United States

No email / No phone

Status: Withdrawn

Research Site

Fort Worth, Texas, 76104, United States

No email / No phone

Status: Withdrawn

Research Site

Houston, Texas, 77054, United States

No email / No phone

Status: Withdrawn

Research Site

Houston, Texas, 77090, United States

No email / No phone

Status: Withdrawn

Research Site

Houston, Texas, 77098, United States

No email / No phone

Status: Withdrawn

Research Site

Kingwood, Texas, 77339, United States

No email / No phone

Status: Withdrawn

Research Site

Dallas, Texas, 75230, United States

No email / No phone

Status: Withdrawn

Research Site

Dallas, Texas, 75246, United States

No email / No phone

Status: Withdrawn

Research Site

Madison, Wisconsin, 53792, United States

No email / No phone

Status: Withdrawn

Research Site

Surrey, GU2 7XX, United Kingdom

No email / No phone

Status: SUSPENDED

Research Site

Atlanta, Georgia, 30318, United States

No email / No phone

Status: SUSPENDED

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: Datopotamab deruxtecan (Dato-DXd, DS-1062)

Overview

Mechanism of action

Efficacy

Safety

Further reading

HealthScout AI Analysis

Eligibility

Show Criteria

Sites (308)

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site